Back to stock research

Verified earnings summary

Research updated: Jul 12, 2026, 12:00 AM UTC

BSX Q1 2026

Boston Scientific's first-quarter 2026 update reflected broad organic growth across cardiovascular and MedSurg franchises, continued product-launch momentum and integration activity while management maintained its growth outlook.

This page provides a source-verified release summary. It does not display a normalized metric table or post-earnings market reaction until those fields are independently verified.

Constructive signals after the release

  • FARAPULSE adoption can expand electrophysiology procedure share and associated catheter demand.
  • WATCHMAN and related structural-heart platforms can benefit from broader physician adoption and indications.
  • A broad cadence of launches across cardiology, endoscopy and urology can sustain above-market procedure growth.

Risks that still need monitoring

  • Regulatory and clinical risk

    Trial outcomes, approval delays or safety signals can slow adoption of important growth platforms.

  • Portfolio integration

    Acquisitions can create integration costs, leverage and execution demands across a rapidly expanding portfolio.

  • Device competition

    Large rivals and new technologies can pressure pricing, physician loyalty and market share.

Primary sources

Q1 2026 Earnings Release and Financial ResultsBoston Scientific Corporation · earningsVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 4/22/2026, 12:00:00 AM

Open original source
Boston Scientific Corporation Investor RelationsBoston Scientific Corporation · companyVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source
Boston Scientific SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 4/22/2026, 12:00:00 AM

Open original source

Continue research

Open risk researchReturn to full stock research